{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:17:05Z","timestamp":1777918625450,"version":"3.51.4"},"reference-count":42,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To assess whether febuxostat use increases the risk of developing cardiovascular (CV) events, cardiac death, and all-cause mortalities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>The relevant literature was searched in several databases including MEDLINE (PubMed, January 1, 1966\u2013February 29, 2020), Web of Science, EMBASE (January 1, 1974\u2013February 29, 2020), ClinicalTrials. gov, and Cochrane Central Register of Controlled Trials. Manual searches for references cited in the original studies and relevant review articles were also performed. All studies included in this metaanalysis were published in English.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>In the end, 20 studies that met our inclusion criteria were included in our metaanalysis. Use of febuxostat was found not to be associated with an increased risk of all-cause mortality (RR 0.87, 95% CI 0.57\u20131.32,<jats:italic>P<\/jats:italic>= 0.51). Also, there was no association between febuxostat use and mortalities arising from CV diseases (CVD; RR 0.84, 95% CI 0.49\u20131.45,<jats:italic>P<\/jats:italic>= 0.53). The RR also revealed that febuxostat use was not associated with CVD events (RR 0.98, 95% CI 0.83\u20131.16,<jats:italic>P<\/jats:italic>= 0.83). Further, the likelihood of occurrence of CVD events was found not to be dependent on febuxostat dose (RR 1.04, 95% CI 0.84\u20131.30,<jats:italic>P<\/jats:italic>= 0.72).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Febuxostat use is not associated with increased risks of all-cause mortality, death from CVD, or CVD events. Accordingly, it is a safe drug for the treatment of gout.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.200307","type":"journal-article","created":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T16:20:14Z","timestamp":1597508414000},"page":"1082-1089","source":"Crossref","is-referenced-by-count":9,"title":["Febuxostat Use and Risks of Cardiovascular Disease Events, Cardiac Death, and All-cause Mortality: Metaanalysis of Randomized Controlled Trials"],"prefix":"10.3899","volume":"48","author":[{"given":"Hao","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Dong","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui Min","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2020,8,15]]},"reference":[{"key":"2022062305300676000_48.7.1082.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.703389"},{"key":"2022062305300676000_48.7.1082.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2014.04.003"},{"key":"2022062305300676000_48.7.1082.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.06.043"},{"key":"2022062305300676000_48.7.1082.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7133.2011.00200.x"},{"key":"2022062305300676000_48.7.1082.5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.atherosclerosis.2018.02.014","article-title":"Elevated serum uric acid predicts the development of moderate coronary artery calcification independent of conventional cardiovascular risk factors","volume":"272","author":"Jun","year":"2018","journal-title":"Atherosclerosis"},{"key":"2022062305300676000_48.7.1082.6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.016379"},{"key":"2022062305300676000_48.7.1082.7","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-018-0757-9"},{"key":"2022062305300676000_48.7.1082.8","unstructured":"ULORIC medication guide. [Internet. Accessed December 15, 2020]. Available from: general.takedapharm.com\/ULORICPI"},{"key":"2022062305300676000_48.7.1082.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.24209"},{"key":"2022062305300676000_48.7.1082.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"2022062305300676000_48.7.1082.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.20935"},{"key":"2022062305300676000_48.7.1082.12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080814"},{"key":"2022062305300676000_48.7.1082.13","doi-asserted-by":"publisher","DOI":"10.1186\/ar2978"},{"key":"2022062305300676000_48.7.1082.14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"2022062305300676000_48.7.1082.15","unstructured":"FDA to evaluate increased risk of heart-related death and death from all causes with the gout medicine febuxostat (Uloric). [Internet. Accessed December 15, 2020]. Available from: www.fda.gov\/media\/108760\/download"},{"key":"2022062305300676000_48.7.1082.16","unstructured":"FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat). [Internet. Accessed December 15, 2020]. Available from: www.fda.gov\/media\/120418\/download"},{"key":"2022062305300676000_48.7.1082.17","doi-asserted-by":"crossref","first-page":"1076189","DOI":"10.1155\/2019\/1076189","article-title":"Febuxostat and cardiovascular events: a systematic review and meta-analysis","volume":"2019","author":"Cuenca","year":"2019","journal-title":"Int J Rheumatol"},{"key":"2022062305300676000_48.7.1082.18","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2018.06.028"},{"key":"2022062305300676000_48.7.1082.19","first-page":"563","article-title":"Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: a 6-months open-label randomized controlled trial","volume":"17","author":"Mukri","year":"2018","journal-title":"EXCLI J"},{"key":"2022062305300676000_48.7.1082.20","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s11739-019-02070-y","article-title":"Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients","volume":"14","author":"Cicero","year":"2019","journal-title":"Intern Emerg Med"},{"key":"2022062305300676000_48.7.1082.21","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for cerebral and cardiorenovascular events prevention study","volume":"40","author":"Kojima","year":"2019","journal-title":"Eur Heart J"},{"key":"2022062305300676000_48.7.1082.22","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/eurheartj\/ehz154","article-title":"Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data","volume":"40","author":"Singh","year":"2019","journal-title":"Eur Heart J"},{"key":"2022062305300676000_48.7.1082.23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/acr.20680","article-title":"Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol","volume":"64","author":"Chohan","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2022062305300676000_48.7.1082.24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv317"},{"key":"2022062305300676000_48.7.1082.25","doi-asserted-by":"publisher","DOI":"10.1177\/2054358116675343"},{"key":"2022062305300676000_48.7.1082.26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijcme.2015.07.001","article-title":"Effects of febuxostat and allopurinol on the inflammation and cardiac function in chronic heart failure patients with hyperuricemia","volume":"8","author":"Nakagomi","year":"2015","journal-title":"IJC Metabolic & Endocrine"},{"key":"2022062305300676000_48.7.1082.27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006683"},{"key":"2022062305300676000_48.7.1082.28","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12266"},{"key":"2022062305300676000_48.7.1082.29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-13-15"},{"key":"2022062305300676000_48.7.1082.30","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/art.39654","article-title":"Impact of febuxostat on renal function in gout subjects with moderate-to-severe renal impairment","volume":"68","author":"Saag","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022062305300676000_48.7.1082.31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.40685","article-title":"Efficacy and safety of febuxostat extended and immediate release in patients with gout and renal impairment: phase III placebo-controlled study","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022062305300676000_48.7.1082.32","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/art.40233","article-title":"Effects of febuxostat in early gout: a randomized, double-blind, placebo-controlled study","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022062305300676000_48.7.1082.33","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1097\/RHU.0b013e31821d36cc","article-title":"Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in Japan: late phase 2 clinical study","volume":"17","author":"Kamatani","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"2022062305300676000_48.7.1082.34","first-page":"393","article-title":"Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor","volume":"10","author":"Foody","year":"2017","journal-title":"Am Health Drug Benefits"},{"key":"2022062305300676000_48.7.1082.35","unstructured":"ICD-9-CM Official Guidelines for Coding and Reporting. [Internet. Accessed December 15, 2020]. Available from: www.findacode.com\/icd-9\/icd-9-cm-guidelines.html."},{"key":"2022062305300676000_48.7.1082.36","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jsxm.2016.04.073","article-title":"Hyperuricemia Is an Independent Risk Factor for Erectile Dysfunction","volume":"13","author":"Long","year":"2016","journal-title":"J Sex Med"},{"key":"2022062305300676000_48.7.1082.37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12967-015-0578-x","article-title":"Febuxostat pretreatment attenuates myocardial ischemia\/reperfusion injury via mitochondrial apoptosis","volume":"2","author":"Wang","year":"2015","journal-title":"J Transl Med"},{"key":"2022062305300676000_48.7.1082.38","doi-asserted-by":"publisher","DOI":"10.1081\/DMR-120037569"},{"key":"2022062305300676000_48.7.1082.39","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cbi.2015.05.013","article-title":"Febuxostat ameliorates doxorubicin-induced cardiotoxicity in rats","volume":"237","author":"Krishnamurthy","year":"2015","journal-title":"Chem Biol Interact"},{"key":"2022062305300676000_48.7.1082.40","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.3390\/ijms20194680","article-title":"Xanthine oxidase inhibitor febuxostat exerts an anti-inflammatory action and protects against diabetic nephropathy development in KK-Ay obese diabetic mice","volume":"20","author":"Mizuno","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2022062305300676000_48.7.1082.41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11906-017-0793-3","article-title":"The effect of xanthine oxidase inhibitors on blood pressure and renal function","volume":"19","author":"Bove","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"2022062305300676000_48.7.1082.42","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1594771"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.200307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T07:13:45Z","timestamp":1667805225000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.200307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,15]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,1]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.3899\/jrheum.200307"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.200307","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,15]]}}}